VENTOLIN™ NEBULES

Salbutamol

QUALITATIVE AND QUANTITATIVE COMPOSITION

VENTOLIN nebules 2.5mg: contain a concentration of salbutamol of 0.1% (1mg salbutamol, as the sulphate, in 1ml). Each Nebule contains 2.5ml of solution equivalent to 2.5mg salbutamol.

VENTOLIN Nebules 5.0mg: contain a concentration of salbutamol of 0.2% (2mg salbutamol, as the sulphate, in 1ml). Each Nebule contains 2.5ml of solution equivalent to 5.0mg salbutamol.

PHARMACEUTICAL FORM

Nebuliser solution.

CLINICAL PARTICULARS

Indications

VENTOLIN Nebules are indicated for use in the routine management of chronic bronchospasm (unresponsive to conventional therapy) and in the treatment of acute severe asthma (status asthmaticus).

Dosage and Administration

Adults and Children

A suitable starting dose of salbutamol by wet inhalation is 2.5 milligrams. This may be increased to 5 milligrams.

Treatment may be repeated four times daily.

Clinical efficacy of nebulised salbutamol in infants under 18 months is uncertain. As transient hypoxaemia may occur, supplemental oxygen therapy should be considered.

VENTOLIN Nebules are intended to be used undiluted. However, if prolonged delivery time is desirable (more than 10 minutes) dilution using sterile normal saline as a diluent may be required.
VENTOLIN Nebules are to be used with a nebuliser, under the direction of a physician.

The solution must not be injected, or swallowed.

Increasing use of beta-2agonists may be a sign of worsening asthma. Under these conditions a reassessment of the patient's therapy plan may be required and concomitant glucocorticosteroid therapy should be considered.

Delivery of the aerosol may be by facemask, 'T' piece or via an endotracheal tube. Intermittent positive pressure ventilation may be used but is rarely necessary. When there is a risk of anoxia through hypoventilation, oxygen should be added to the inspired air.

As there may be adverse effects associated with excessive dosing, the dosage or frequency of administration should only be increased on medical advice.

As many nebulisers operate on a continuous flow basis, it is likely that nebulised drug will be released in the local environment. VENTOLIN Nebules should therefore be administered in a well ventilated room, particularly in hospitals when several patients may be using nebulisers in the same space at the same time.

**Contraindications**

VENTOLIN Nebules are contraindicated in patients with a history of hypersensitivity to any of their components.

Non-i.v. formulations of VENTOLIN must not be used to arrest uncomplicated premature labour or threatened abortion. VENTOLIN presentations should not be used for threatened abortion during the first or second trimesters of pregnancy.

**Warnings and Precautions**

The management of asthma should normally follow a stepwise programme, and patient response should be monitored clinically and by lung function tests.

Increasing use of short-acting inhaled beta-2agonists to control symptoms indicates deterioration of asthma control. Under these conditions, the patient's therapy plan should be reassessed. Sudden and progressive deterioration in asthma control is potentially life threatening and consideration should be given to starting or increasing corticosteroid therapy. In patients considered at risk, daily peak flow monitoring may be instituted.

**VENTOLIN** Nebules must only be used by inhalation, to be breathed in through the mouth, and must not be injected or swallowed.
Patients receiving treatment at home with VENTOLIN Nebules must be warned that if either the usual relief is diminished or the usual duration of action reduced, they should not increase the dose or its frequency of administration, but should seek medical advice.

VENTOLIN Nebules should be used with caution in patients known to have received large doses of other sympathomimetic drugs.

VENTOLIN should be administered cautiously to patients with thyrotoxicosis.

A small number of cases of acute angle closure glaucoma have been reported in patients treated with a combination of nebulised VENTOLIN and ipratropium bromide. A combination of nebulised VENTOLIN with nebulised anticholinergics should therefore be used cautiously. Patients should receive adequate instruction in correct administration and be warned not to let the solution or mist enter the eye.

Potentially serious hypokalaemia may result from beta-2-agonist therapy mainly from parenteral and nebulised administration. Particular caution is advised in acute severe asthma as this effect may be potentiated by concomitant treatment with xanthine derivatives, steroids, diuretics and by hypoxia. It is recommended that serum potassium levels are monitored in such situations.

As with other inhalation therapy, paradoxical bronchospasm may occur, resulting in an immediate increase in wheezing after dosing. This should be treated immediately with an alternative presentation or a different fast-acting inhaled bronchodilator, if immediately available. VENTOLIN nebules should be discontinued, and if necessary a different fast-acting bronchodilator instituted for ongoing use.

In common with other beta-adrenoceptor agonists, VENTOLIN can induce reversible metabolic changes, for example increased blood sugar levels.

The diabetic patient may be unable to compensate for this and the development of ketoacidosis has been reported. Concurrent administration of corticosteroids can exaggerate this effect.

Lactic acidosis has been reported very rarely in association with high therapeutic doses of intravenous and nebulised short-acting beta-agonist therapy, mainly in patients being treated for an acute asthma exacerbation (see Adverse Reaction section). Increase in lactate levels may lead to dyspnoea and compensatory hyperventilation, which could be misinterpreted as a sign of asthma treatment failure and lead to inappropriate intensification of short-acting beta-agonist treatment. It is therefore recommended that patients are monitored for the development of elevated serum lactate and consequent metabolic acidosis in this setting.

**Interactions**

VENTOLIN and non-selective beta-blocking drugs, such as propranolol, should not
usually be prescribed together.

VENTOLIN is not contraindicated in patients under treatment with monoamine oxidase inhibitors (MAOIs).

**Pregnancy and Lactation**

**Fertility**

There is no information on the effects of VENTOLIN on human fertility. There were no adverse effects on fertility in animals (see Pre-clinical Safety Data).

**Pregnancy**

Administration of drugs during pregnancy should only be considered if the expected benefit to the mother is greater than any possible risk to the foetus.

**Lactation**

As salbutamol is probably secreted in breast milk its use in nursing mothers is not recommended unless the expected benefits outweigh any potential risk. It is not known whether salbutamol in breast milk has a harmful effect on the neonate.

**Effects on Ability to Drive and Use Machines**

None reported.

**Adverse Reactions**

Adverse events are listed below by system organ class and frequency. Frequencies are defined as: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1000 to <1/100), rare (≥1/10,000 to <1/1000) and very rare (≥1/10,000) including isolated reports. Very common and common events were generally determined from clinical trial data. Rare and very rare events were generally determined from spontaneous data.

**Immune system disorders**

Very rare: Hypersensitivity reactions including angioedema, urticaria, bronchospasm, hypotension and collapse.

**Metabolism and nutrition disorders**

Rare: Hypokalaemia.

Potentially serious hypokalaemia may result from beta-2-agonist therapy.

Very rare: Lactic acidosis

Lactic acidosis has been reported very rarely in patients receiving intravenous and nebulised salbutamol therapy for the treatment of acute asthma exacerbation.
Nervous system disorders
Common: Tremor, headache.
Very rare: Hyperactivity.

Cardiac disorders
Common: Tachycardia.
Uncommon: Palpitations
Very rare: Cardiac arrhythmias including atrial fibrillation, supraventricular tachycardia and extrasystoles.

Vascular disorders
Rare: Peripheral vasodilatation.

Respiratory, thoracic and mediastinal disorders
Very rare: Paradoxical bronchospasm.

Gastrointestinal disorders
Uncommon: Mouth and throat irritation.

Musculoskeletal and connective tissue disorders
Uncommon: Muscle cramps.

Overdose

The most common signs and symptoms of overdose with VENTOLIN are transient beta agonist pharmacologically mediated events (see Warnings and Precautions and Adverse Reactions).

Hypokalaemia may occur following overdosage with VENTOLIN. Serum potassium levels should be monitored.
Lactic acidosis has been reported in association with high therapeutic doses as well as overdoses of short-acting beta-agonist therapy, therefore monitoring for elevated serum lactate and consequent metabolic acidosis (particularly if there is persistence or worsening of tachypnea despite resolution of other signs of bronchospasm such as wheezing) may be indicated in the setting of overdose.

**PHARMACOLOGICAL PROPERTIES**

**Pharmacodynamics**

Salbutamol is a selective beta₂-adrenoceptor agonist. At therapeutic doses it acts on the beta₂-adrenoceptors of bronchial muscle providing short acting (4 to 6 hour) bronchodilation with a fast onset (within 5 minutes) in reverse airways obstruction.

**Pharmacokinetics**

**Absorption**

After administration by the inhaled route, between 10 and 20% of the dose reaches the lower airways. The remainder is retained in the delivery system or is deposited in the oropharynx from where it is swallowed. The fraction deposited in the airways is absorbed into the pulmonary tissues and circulation but is not metabolised by the lung.

**Distribution**

Salbutamol is bound to plasma proteins to the extent of 10%.

**Metabolism**

On reaching the systemic circulation it becomes accessible to hepatic metabolism and is excreted, primarily in the urine, as unchanged drug and as the phenolic sulphate.

The swallowed portion of an inhaled dose is absorbed from the gastrointestinal tract and undergoes considerable first-pass metabolism to the phenolic sulphate. Both unchanged drug and conjugate are excreted primarily in the urine.

**Elimination**

Salbutamol administered intravenously has a half-life of four to six hours and is cleared partly renally and partly by metabolism to the inactive 4’-O-sulphate (phenolic sulphate) which is also excreted primarily in the urine. The faeces are a minor route of excretion. The majority of a dose of salbutamol given intravenously, orally or by inhalation is excreted within 72 hours.
Pre-clinical Safety Data

In common with other potent selective beta₂ receptor agonists, salbutamol has been shown to be teratogenic in mice when given subcutaneously. In a reproductive study, 9.3% of fetuses were found to have cleft palate, at 2.5 mg/kg, 4 times the maximum human oral dose. In rats, treatment at the levels of 0.5, 2.32, 10.75, and 50mg/kg/day orally throughout pregnancy resulted in no significant foetal abnormalities. The only toxic effect was an increase in neonatal mortality at the highest dose level as the result of lack of maternal care. A reproductive study in rabbits revealed cranial malformations in 37% of fetuses at 50mg/kg/day, 78 times the maximum human oral dose.

In an oral fertility and general reproductive performance study in rats at doses of 2 and 50 mg/kg/day, with the exception of a reduction in number of weanlings surviving to day 21 post partum at 50 mg/kg/day, there were no adverse effects on fertility, embryofetal development, litter size, birth weight or growth rate.

PHARMACEUTICAL PARTICULARS

Special Precautions for Storage

VENTOLIN Nebules should be stored at a temperature below 30ºC and protected from light.

Nature and Contents of Container

VENTOLIN Nebules are plastic ampoules containing a solution of salbutamol sulphate in normal saline. Each Nebule contains 2.5ml of solution.

Instructions for Use/Handling

Dilution:

VENTOLIN Nebules may be diluted with sterile normal saline. Any unused solution in the chamber of the nebuliser must be discarded.
Not all presentations are available in every country.

Manufactured by GlaxoSmithKline Australia Pty Ltd, Boronia, Australia

Version number: GDS25/IPI09(SI)

Date of issue: 14 April 2014

VENTOLIN is a trademark of the GlaxoSmithKline group of companies

[GlaxoSmithKline logo]